BACKGROUND: Natural killer cells are known to have anti-tumor activity in haploidentical hematopoietic stem cell transplantation. We hypothesized that reconstituted circulating natural killer cells may be associated with improved relapse-free survival after HLA-matched hematopoietic stem cell transplantation. DESIGN AND METHODS: Serial peripheral blood absolute natural killer cell counts were prospectively measured by flow cytometry of lymphocytes expressing CD56 and CD16 in 167 patients. Cluster analysis was used at engraftment and 60 days post-transplant to distinguish patients with high and low absolute natural killer cell counts. At engraftment 80 patients had high counts (> 22.2/mm3) and 43 had low counts. At 60 days post-transplant 84 patients had high counts (> 18.2/mm3) and 38 had low counts. The primary study end-points were death, relapse and acute graft-versus-host disease. The median follow-up was 373 days (range, 67-1767). RESULTS: Among patients given reduced intensity conditioning, a low absolute natural killer cell count at 60 days post-transplant was independently associated with relapse [adjusted hazard ratio (AHR) = 28.4, 95% confidence interval (CI) 4.3-186.4] and death (AHR = 17.5, 95% CI 4.3-71.3). Furthermore, patients given reduced intensity conditioning who had a high absolute natural killer cell count at 60 days had a significantly better 1-year survival than those with a low count by Kaplan-Meier analysis (83% vs. 11%, p<0.001). Multivariate analysis confirmed that low 60-day absolute natural killer count in patients given reduced intensity conditioning was independently associated with an increase in relapse or death (AHR = 20.22, 95% CI 4.76-85.40). In contrast, there was no significant association between 60-day absolute natural killer cell counts and clinical outcomes in patients receiving myeloablative conditioning. There was no significant association between absolute natural killer cell count and graft-versus-host disease. CONCLUSIONS: High natural killer cell reconstitution is associated with reduced relapse and death without an increased incidence of graft-versus-host-disease after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation. Measuring reconstituted natural killer cells expressing CD56(+)/CD16(+) post-transplant may have novel prognostic and therapeutic implications.
BACKGROUND: Natural killer cells are known to have anti-tumor activity in haploidentical hematopoietic stem cell transplantation. We hypothesized that reconstituted circulating natural killer cells may be associated with improved relapse-free survival after HLA-matched hematopoietic stem cell transplantation. DESIGN AND METHODS: Serial peripheral blood absolute natural killer cell counts were prospectively measured by flow cytometry of lymphocytes expressing CD56 and CD16 in 167 patients. Cluster analysis was used at engraftment and 60 days post-transplant to distinguish patients with high and low absolute natural killer cell counts. At engraftment 80 patients had high counts (> 22.2/mm3) and 43 had low counts. At 60 days post-transplant 84 patients had high counts (> 18.2/mm3) and 38 had low counts. The primary study end-points were death, relapse and acute graft-versus-host disease. The median follow-up was 373 days (range, 67-1767). RESULTS: Among patients given reduced intensity conditioning, a low absolute natural killer cell count at 60 days post-transplant was independently associated with relapse [adjusted hazard ratio (AHR) = 28.4, 95% confidence interval (CI) 4.3-186.4] and death (AHR = 17.5, 95% CI 4.3-71.3). Furthermore, patients given reduced intensity conditioning who had a high absolute natural killer cell count at 60 days had a significantly better 1-year survival than those with a low count by Kaplan-Meier analysis (83% vs. 11%, p<0.001). Multivariate analysis confirmed that low 60-day absolute natural killer count in patients given reduced intensity conditioning was independently associated with an increase in relapse or death (AHR = 20.22, 95% CI 4.76-85.40). In contrast, there was no significant association between 60-day absolute natural killer cell counts and clinical outcomes in patients receiving myeloablative conditioning. There was no significant association between absolute natural killer cell count and graft-versus-host disease. CONCLUSIONS: High natural killer cell reconstitution is associated with reduced relapse and death without an increased incidence of graft-versus-host-disease after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation. Measuring reconstituted natural killer cells expressing CD56(+)/CD16(+) post-transplant may have novel prognostic and therapeutic implications.
Authors: Luke Maggs; Francesca Kinsella; Y L Tracey Chan; Suzy Eldershaw; Duncan Murray; Jane Nunnick; Joanne Bird; Charles Craddock; Jianmin Zuo; Ram Malladi; Paul Moss Journal: Blood Adv Date: 2017-08-21
Authors: Ioannis Politikos; Jessica A Lavery; Patrick Hilden; Christina Cho; Taylor Borrill; Molly A Maloy; Sergio A Giralt; Marcel R M van den Brink; Miguel-Angel Perales; Juliet N Barker Journal: Blood Adv Date: 2020-01-14
Authors: Stefan O Ciurea; Jolie R Schafer; Roland Bassett; Cecele J Denman; Kai Cao; Dana Willis; Gabriela Rondon; Julianne Chen; Doris Soebbing; Indreshpal Kaur; Alison Gulbis; Sairah Ahmed; Katayoun Rezvani; Elizabeth J Shpall; Dean A Lee; Richard E Champlin Journal: Blood Date: 2017-08-23 Impact factor: 22.113
Authors: David A Rizzieri; Christopher Crout; Robert Storms; Jared Golob; Gwynn D Long; Cristina Gasparetto; Keith M Sullivan; Mitchell Horwitz; John Chute; Anand S Lagoo; Ashley Morris; Anne Beaven; Yiping Yang; Bercedis Peterson; Zhiguo Li; Nelson J Chao Journal: Cancer Invest Date: 2011-01 Impact factor: 2.176
Authors: Monzr M Al Malki; Mary Horowitz; Rupert Handgretinger; Wing Leung; Denis-Claude Roy; Xiao-Jun Huang; Ephraim Fuchs; Franco Locatelli; Didier Blaise; Shin Mineishi; Massimo Martelli; Jeffrey Miller; Carl June; Hui-Sheng Ai; Leo Luznik; Domenico Mavilio; Enrico Lugli; Marcel R M van den Brink; Richard E Champlin; Stefan O Ciurea Journal: Biol Blood Marrow Transplant Date: 2016-01-13 Impact factor: 5.742